Radotinib HCl

Phase 3Small molecule

IIl-Yang Pharm. Co., Ltd.

Radotinib HCl is one of 47 small molecule programs targeting Parkinson disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseActive, not recruiting

Chronic Myeloid Leukemia, Chronic PhaseRecruiting

Parkinson DiseasePhase 2

Active, not recruiting

Chronic Myeloid Leukemia, Chronic PhasePhase 3

Recruiting

Competition

Competitive Landscape

91 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Brintellix

Takeda

Approved

1 2

Aricept

Eisai

Approved

1 3

Exelon

Novartis

Approved

1 4

Northera

Lundbeck

Approved

1 5

Myrbetriq

Astellas

Approved

1 6

Medrol

Pfizer

Approved

1 7

Nourianz

Kyowa Kirin Co., Ltd.

Avelox

Nicorette

Epidiolex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Parkinson Disease

NCT04691661

Q4 2027

Active, not recruiting

Chronic Myelogenous Leukemia

NCT06665412

Q2 2028

Phase 3Recruiting

Chronic Myeloid Leukemia, Chronic Phase

NCT03459534

Clinical

Trials by Indication[1]

Clinical Trial1 trial

Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 1·NCT06461078·24 enrolled

Parkinson disease1 trial

A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease

Active, not recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 2·NCT04691661·43 enrolled

Chronic Myeloid Leukemia, Chronic Phase1 trial

A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib

Recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT03459534·173 enrolled

Chronic Myelogenous Leukemia1 trial

A Single-arm, Open-label, Multicenter, Investigator-led Observational Study to Evaluate the Efficacy and Safety of Dose Reduction of Radotinib as a First-line Treatment in Patients With Newly Diagnosed Chronic Phase Ph+ Chronic Myeloid Leukemia.

Active, not recruiting·IIl-Yang Pharm. Co., Ltd.··NCT06665412·169 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Radotinib HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radotinib HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radotinib HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Il-Yang Pharm. Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIl-Yang Pharm. Co., Ltd.

Radotinib HCl

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Clinical Trial1 trial

Parkinson disease1 trial

Chronic Myeloid Leukemia, Chronic Phase1 trial

Chronic Myelogenous Leukemia1 trial

References

Drug Info

Quick Facts

Related News